Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats

Journal of Hypertension

Volumn 36, Issue 2, 2018, Pages 368-376

  Martínez Martínez, Ernesto ^a   Ibarrola, Jaime ^a   Fernández Celis, Amaya ^a   Calvier, Laurent ^b   Leroy, Celine ^b   Cachofeiro, Victoria ^c   Rossignol, Patrick ^b   López Andrés, Natalia ^a,b  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b INSERM   (France)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

fibrosis; galectin 3; kidney; SHR

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; B7 ANTIGEN; BETA CATENIN; BIOLOGICAL MARKER; CD45 ANTIGEN; CHLORDANE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DRINKING WATER; FIBRONECTIN; GALECTIN 3; HERMES ANTIGEN; MODIFIED CITRUS PECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PECTIN; PROTEIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIN; ACUTE PHASE PROTEIN; CCL2 PROTEIN, RAT; LEUKOCYTE ANTIGEN; LIPOCALIN; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN PROTEIN, RAT; ONCOPROTEIN; SMOOTH MUSCLE ACTIN, RAT; SPP1 PROTEIN, RAT;

ACUTE KIDNEY FAILURE; ALBUMINURIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; HISTOLOGY; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY MASS; KIDNEY TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT DURATION; ANIMAL; BLOOD; BLOOD PRESSURE; CELL LINE; COMPLICATION; FIBROSIS; HYPERTENSION; KIDNEY; KIDNEY DISEASE; METABOLISM; ORGAN SIZE; PATHOLOGY; UPREGULATION; URINE;

ACTINS; ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ALBUMINURIA; ANIMALS; ANTIGENS, CD; BETA CATENIN; BLOOD PRESSURE; CELL LINE; CHEMOKINE CCL2; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; FIBROSIS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; LIPOCALINS; MALE; ORGAN SIZE; OSTEOPONTIN; PECTINS; PROTO-ONCOGENE PROTEINS; RATS; RATS, INBRED SHR; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 85039714888     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001545     Document Type: Article

References (34)

1. Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, et al., European Renal Association European Dialysis; Transplant Association (ERA-EDTA) European Renal; Cardiovascular Medicine (EURECA-m) Working Group. Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol 2016; 4:360-373.
2. Frenay AR, Yu L, van der Velde AR, Vreeswijk-Baudoin I, Lopez-Andres N, van Goor H, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol 2015; 308:F500-509.
3. Singh S, Manson SR, Lee H, Kim Y, Liu T, Guo Q, et al. Tubular overexpression of angiopoietin-1 attenuates renal fibrosis. PLoS One 2016; 11:e0158908.
4. Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014; 351:336-343.
5. Lu W, Liu S, Zhao Z, Liu Y, Li T. The effect of connective tissue growth factor on renal fibrosis and podocyte injury in hypertensive rats. Ren Fail 2014; 36:1420-1427.
6. Palatini P, Mormino P, Dorigatti F, Santonastaso M, Mos L, De Toni R, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: The harvest. Kidney Int 2006; 70:578-584.
7. Miana M, de Las Heras N, Rodriguez C, Sanz-Rosa D, Martin-Fernandez B, Mezzano S, et al. Effect of eplerenone on hypertension-Associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-gamma). J Physiol Pharmacol 2011; 62:87-94.
8. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46:412-418.
9. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sadaba JR, et al. The impact of galectin-3 inhibition on aldosteroneinduced cardiac and renal injuries. JACC Heart Fail 2015; 3:59-67.
10. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110:3121-3128.
11. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11:811-817.
12. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28:433-440.
13. OSeaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 2013; 24:1470-1477.
14. Glinsky VV, Raz A. Modified citrus pectin antimetastatic properties: one bullet, multiple targets. Carbohydr Res 2009; 344:1788-1791.
15. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One 2011; 6:e18683.
16. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007; 9: 662-670.
17. Martinez-Martinez E, Calvier L, Fernandez-Celis A, Rousseau E, Jurado-Lopez R, Rossoni LV, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension 2015; 66:767-775.
18. Martinez-Martinez E, Lopez-Andres N, Jurado-Lopez R, Rousseau E, Bartolome MV, Fernandez-Celis A, et al. Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension 2015; 66:961-969.
19. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172:288-298.
20. Dang Z, MacKinnon A, Marson LP, Sethi T. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 2012; 93:477-484.
21. Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, et al. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 2000; 157:815-823.
22. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by antithy1.1 antibodies. J Pathol 1999; 187:481-489.
23. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, et al. Accelerated diabetic glomerulopathy in galectin-3/age receptor 3 knockout mice. FASEB J 2001; 15:2471-2479.
24. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108:385-390.
25. Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-Term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (cardiac resynchronization in heart failure) trial. Eur J Heart Fail 2012; 14:74-81.
26. Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 2000; 9:133-138.
27. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112:1486-1494.
28. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994; 266:F829-F842.
29. Martinez-Martinez E, Jurado-Lopez R, Valero-Munoz M, Bartolome MV, Ballesteros S, Luaces M, et al. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J Hypertens 2014; 32:1104-1114; discussion 1114.
30. de las Heras N, Ruiz-Ortega M, Ruperez M, Sanz-Rosa D, Miana M, Aragoncillo P, et al. Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II. J Renin Angiotensin Aldosterone Syst 2006; 7:192-200.
31. Lee HS, Kim C, Kim SB, Kim MG, Park D. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Biochem Biophys Res Commun 2010; 395:553-559.
32. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21:212-222.
33. Kimura K, Suzuki N, Ohba S, Nagai R, Hiroi J, Mise N, et al. Hypertensive glomerular damage as revealed by the expression of alpha-smooth muscle actin and nonmuscle myosin. Kidney Int Suppl 1996; 55: S169-172.
34. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta 2015; 438:350-357.